Non-invasive physical plasma for preventing radiation dermatitis in breast cancer: Results from an intrapatient-randomised double-blind placebo-controlled trial.
Breast cancer
Cold atmospheric plasma
Non-invasive physical plasma
Radiation dermatitis
Radiation therapy
Randomised controlled trial
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
31
10
2023
accepted:
02
11
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
To investigate the effect of topical non-invasive physical plasma (NIPP), a volatile mix generated out of ambient air, on prevention of acute radiation dermatitis (RD) during and after whole-breast irradiation (WBI). Lateral and medial breast halves were randomised within each patient to receive either 120 s of NIPP or sham treatment daily during WBI. Standard skin care with urea lotion was applied to the whole breast. Blinded acute skin toxicity was assessed weekly for each breast half separately and included clinician- (CTCAE) and patient-reported (modified RISRAS), and objective (spectrophotometry) assessments. As an additional external control, a comparable standard of care (SoC) patient collective from a previous prospective trial was used. Sixty-four patients were included. There were no significant differences between breast halves. Post-hoc comparison with a similar SoC control collective revealed OR = 0.28 (95% CI 0.11-0.76; Even though there were no differences between intrapatient-randomised breast halves, the overall incidence and severity of acute radiation-induced skin toxicity were considerably lower when compared to a prospectively collected SoC cohort. Our data suggest the potential benefit of NIPP in RD prevention. A randomised trial with a physical control group is warranted to confirm these promising results (DRKS00026225).
Sections du résumé
Background and Purpose
UNASSIGNED
To investigate the effect of topical non-invasive physical plasma (NIPP), a volatile mix generated out of ambient air, on prevention of acute radiation dermatitis (RD) during and after whole-breast irradiation (WBI).
Materials and Methods
UNASSIGNED
Lateral and medial breast halves were randomised within each patient to receive either 120 s of NIPP or sham treatment daily during WBI. Standard skin care with urea lotion was applied to the whole breast. Blinded acute skin toxicity was assessed weekly for each breast half separately and included clinician- (CTCAE) and patient-reported (modified RISRAS), and objective (spectrophotometry) assessments. As an additional external control, a comparable standard of care (SoC) patient collective from a previous prospective trial was used.
Results
UNASSIGNED
Sixty-four patients were included. There were no significant differences between breast halves. Post-hoc comparison with a similar SoC control collective revealed OR = 0.28 (95% CI 0.11-0.76;
Conclusion
UNASSIGNED
Even though there were no differences between intrapatient-randomised breast halves, the overall incidence and severity of acute radiation-induced skin toxicity were considerably lower when compared to a prospectively collected SoC cohort. Our data suggest the potential benefit of NIPP in RD prevention. A randomised trial with a physical control group is warranted to confirm these promising results (DRKS00026225).
Identifiants
pubmed: 38021092
doi: 10.1016/j.ctro.2023.100699
pii: S2405-6308(23)00124-6
pmc: PMC10654149
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100699Informations de copyright
© 2023 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Environ Mol Mutagen. 2018 May;59(4):268-277
pubmed: 29417643
mSphere. 2021 Jun 16;:e0021721
pubmed: 34133202
Drug Saf. 2015 May;38(5):493-509
pubmed: 25862024
J Pathol. 2019 Nov;249(3):368-380
pubmed: 31265742
Support Care Cancer. 2022 Jun;30(6):4663-4674
pubmed: 35067732
Br J Nurs. 1999 Oct 28-Nov 10;8(19):1305-12
pubmed: 10887808
Cancer Treat Res Commun. 2021;28:100403
pubmed: 34082363
Clin Breast Cancer. 2018 Oct;18(5):e825-e840
pubmed: 30072193
J Dtsch Dermatol Ges. 2018 Jan;16(1):7-13
pubmed: 29211323
J Am Acad Dermatol. 2022 Jan;86(1):161-163
pubmed: 30878566
JAMA Oncol. 2023 Jul 1;9(7):962-965
pubmed: 37140927
Radiother Oncol. 2020 May;146:172-179
pubmed: 32171945
Radiother Oncol. 1994 Mar;30(3):213-21
pubmed: 8209004
Int J Mol Sci. 2017 Apr 19;18(4):
pubmed: 28422070
Support Care Cancer. 2023 Jun 6;31(7):382
pubmed: 37280403
Microvasc Res. 2016 Jul;106:8-13
pubmed: 26944583
In Vivo. 2020 Nov-Dec;34(6):3103-3107
pubmed: 33144413
JAMA Oncol. 2015 Oct;1(7):931-41
pubmed: 26247543
J Dtsch Dermatol Ges. 2015 Feb;13(2):143-50
pubmed: 25597338
Cancers (Basel). 2020 Aug 28;12(9):
pubmed: 32872216
Breast. 2023 Oct;71:31-41
pubmed: 37473629
Wound Repair Regen. 2023 May-Jun;31(3):415-417
pubmed: 36861202
Strahlenther Onkol. 2005 Jun;181(6):392-5
pubmed: 15925982
Am J Clin Oncol. 2004 Aug;27(4):361-3
pubmed: 15289728
PLoS One. 2013 Nov 12;8(11):e79325
pubmed: 24265766
JAMA Oncol. 2022 Jun 1;8(6):887-894
pubmed: 35446337
Br J Hosp Med (Lond). 2022 Feb 2;83(2):1-7
pubmed: 35243878
Oxid Med Cell Longev. 2019 Sep 3;2019:3873928
pubmed: 31565150
Sci Rep. 2020 Jun 26;10(1):10440
pubmed: 32591594
Radiother Oncol. 2015 Jan;114(1):3-10
pubmed: 25630428
J Pain Symptom Manage. 2019 Jul;58(1):92-99.e1
pubmed: 30974233
J Clin Med. 2023 Jun 22;12(13):
pubmed: 37445247
Int Wound J. 2019 Feb;16(1):103-111
pubmed: 30311743
Breast Cancer (Dove Med Press). 2017 Mar 06;9:121-126
pubmed: 28293119
PLoS One. 2016 Sep 01;11(9):e0160667
pubmed: 27584003
Acta Oncol. 2018 Jul;57(7):908-915
pubmed: 29463159
Anticancer Res. 2017 Oct;37(10):5343-5353
pubmed: 28982842
J Appl Microbiol. 2017 May;122(5):1134-1148
pubmed: 28106311
Breast J. 2019 Sep;25(5):942-947
pubmed: 31165586
Lancet Oncol. 2023 Apr;24(4):e172-e185
pubmed: 36990615
Biomol Ther (Seoul). 2014 Nov;22(6):477-90
pubmed: 25489414
JAMA Oncol. 2023 Jul 1;9(7):940-945
pubmed: 37140904
Pharmaceutics. 2022 Aug 24;14(9):
pubmed: 36145515
Int J Radiat Biol. 1994 Jan;65(1):27-33
pubmed: 7905906
Polymers (Basel). 2019 Dec 16;11(12):
pubmed: 31888185
Radiother Oncol. 2021 Jun;159:98-105
pubmed: 33771577
Appl Microbiol Biotechnol. 2021 Mar;105(5):2057-2070
pubmed: 33587156
Strahlenther Onkol. 2023 Oct;199(10):891-900
pubmed: 37099166
Biomedicines. 2022 Apr 13;10(4):
pubmed: 35453639
Urologe A. 2019 Jun;58(6):673-679
pubmed: 30097666
Exp Dermatol. 2012 Dec;21(12):921-5
pubmed: 23171452
PLoS One. 2019 Apr 9;14(4):e0215099
pubmed: 30964925
JAMA Netw Open. 2020 Jul 1;3(7):e2010411
pubmed: 32672829